SEARCH RESULTS FOR:
Alexander Donau
APAC REGIONAL HEAD, LESCHACO
"Though a major change in the design and organization of global supply chains does not happen overnight, we do see a lot more caution in the medium-to-long-term planning."
Russell Trenary
PRESIDENT & CEO, OUTLOOK THERAPEUTICS
United States Life Sciences 2022
"If our ophthalmic bevacizumab is approved, we will potentially enhance the standard of care for patients with disorders like wet AMD, diabetic macular edema, and branch retinal vein occlusion by removing concerns related to off-label repackaged IV product."
Albert Friesen
CEO & CHAIRMAN OF THE BOARD, MEDICURE INC.
United States Life Sciences 2022
"Our recently launched e-commerce site for Marley Drug has huge potential and will be our most significant driver of growth and major source of our profits moving forward."
Guillermo Barreda
GERENTE GENERAL, KNIGHT PIÉSOLD PERÚ
Knight Piésold elaborates on the company’s experience in engineering and environmental services. (Spanish interview)
Arturo Molina
MANAGING DIRECTOR – MEXICO, COVESTRO
Covestro Mexico explains its initiatives towards a circular economy.
Gina Fyffe
CEO, INTEGRA PETROCHEMICALS
Singapore Chemicals 2021
Integra Petrochemicals in Singapore describes how it manages the challenges of today’s confusing market place.
Olga Potapova
FOUNDER, CEO & SCIENTIFIC DIRECTOR, CURELINE
Cureline updates GBR on its global activities.
Jennifer Cannon
SVP GLOBAL HEAD OF MAMMALIAN BIOLOGICS, LONZA
"Our fixed-price, fastest DNA-to-IND program is packaged in a standardized platform to allow clients to bring a new antibody molecule to IND filing in a rapid amount of time."
Mark Egerton
CEO, QUOTIENT SCIENCES
"The focus of our integrated Translational Pharmaceutics programs is to provide the customer with a development platform capable of responding in real-time to emerging development data and maintain an overall timeline to proof of concept."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
MACIG 2025 - Mining in Africa Country Investment Guide
It is said that mining is a patient industry. Current demand projections are not. Demand for minerals deemed ‘critical’ is set to increase almost fourfold by 2030, according to the UN. Demand for nickel, cobalt and lithium is predicted to double, triple and rise ten-fold, respectively, between 2022 and 2050. The world will need to mine more copper between 2018 and 2050 than it has mined throughout history. 2050 is also the deadline to curb emissions before reaching a point of ‘no return.’ The pace of mineral demand and the consequences of not meeting it force the industry to act fast and take more risks. Mining cannot afford to be a patient industry anymore. The scramble for supply drives miners back to geological credentials, and therefore to places like the African Central Copperbelt.
It is said that mining is a patient industry. Current demand projections are not. Demand for minerals deemed ‘critical’ is set to increase almost fourfold by 2030, according to the UN. Demand for nickel, cobalt and lithium is predicted to double, triple and rise ten-fold, respectively, between 2022 and 2050. The world will need to mine more copper between 2018 and 2050 than it has mined throughout history. 2050 is also the deadline to curb emissions before reaching a point of ‘no return.’ The pace of mineral demand and the consequences of not meeting it force the industry to act fast and take more risks. Mining cannot afford to be a patient industry anymore. The scramble for supply drives miners back to geological credentials, and therefore to places like the African Central Copperbelt.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
